Lab profiles.

Introduction
A study of tumor resectability in pre-operative patients with advanced epithelial ovarian cancer is required to predict primary surgical benefits accurately. This study aims to investigate IL6, CA-125 and HE4 to predict tumor resectability in the pre-operative patients with advanced epithelial ovarian cancer.
Methods
This cross-sectional study was conducted in the polyclinic, oncology and gynecology inpatient room of Dr. M. Jamil Padang Hospital from June until December 2022. Advanced epithelial ovarian cancer stage based on histology result from FIGO stages IIIB–IVA. IL6, CA-125, and HE4 were measured using ECLIA (electrochemiluminescence immunoassay). Categorical data were assessed using Chi-square and Mann-Whitney tests. Numerical variable correlations were analyzed using Pearson Correlation tests. While the correlation between numerical and nominal variables was analyzed using the Eta correlation test. A p-value of <0,05 was considered a significant correlation. The cut-off value of serum IL6, CA-125, and HE4 was determined with a ROC curve. The sensitivity and specificity of each clinical parameter were calculated.
Results
There was a significant difference in IL-6 (1328 vs 752 pg/ml; p<0,001), CA-125 (1260,5 vs 819,5 U/ml; p<0,001), and HE4 levels (1320 vs 760 pmol/L; p<0,001) between patients with tumor resectability of > 1 cm (suboptimal) vs < 1 cm (optimal). There was a correlation between IL6 (r = 0,832), CA-125 (r = 0,716), and HE4 (r = 0,716) with tumor resectability.
Conclusion
Measuring IL6, CA-125, and HE4 levels is useful for clinicians to predict tumor resectability in pre-operative patients with advanced epithelial ovarian cancer.

引言
精准预测晚期上皮性卵巢癌术前患者的肿瘤可切除性，对准确评估初次手术获益至关重要。本研究旨在检测白细胞介素6（IL-6）、糖类抗原125（CA-125）及人附睾蛋白4（HE4）的水平，以预测晚期上皮性卵巢癌术前患者的肿瘤可切除性。
方法
本研究为横断面研究，于2022年6月至12月在M·贾米尔·帕当医院综合门诊、肿瘤科及妇科病房开展。本研究纳入的晚期上皮性卵巢癌患者分期基于组织病理学结果，参照国际妇产科联盟（International Federation of Gynecology and Obstetrics，FIGO）IIIB~IVA期标准。采用电化学发光免疫分析法（electrochemiluminescence immunoassay，ECLIA）检测血清IL-6、CA-125及HE4水平。分类数据采用卡方检验与曼-惠特尼U检验进行分析；数值变量间的相关性采用皮尔逊相关分析；数值变量与名义变量间的相关性则采用Eta相关分析。以P<0.05为差异具有统计学意义。通过受试者工作特征（ROC）曲线确定血清IL-6、CA-125及HE4的截断值，并计算各临床参数的灵敏度与特异度。
结果
肿瘤可切除性>1cm（非最优切除）患者与<1cm（最优切除）患者的IL-6水平[1328 vs 752 pg/ml；P<0.001]、CA-125水平[1260.5 vs 819.5 U/ml；P<0.001]及HE4水平[1320 vs 760 pmol/L；P<0.001]均存在显著组间差异。IL-6（r=0.832）、CA-125（r=0.716）及HE4（r=0.716）水平均与肿瘤可切除性存在显著相关性。
结论
检测血清IL-6、CA-125及HE4水平，可为临床医师预测晚期上皮性卵巢癌术前患者的肿瘤可切除性提供有效参考。